U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187713) titled 'ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases' on Sept. 07.
Brief Summary: This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages. The trial evaluates whether 12 weeks of ACE Reno (1 mL sublingually four times daily) reduces albuminuria/proteinuria and stabilizes kidney function in participants with nephropathy due to diabetes, hypertension, autoimmune disease, reflux/UTI, chronic glomerulonephritis, unknown etiology, pre-dialysis CKD, or post-tr...